The total number of shares and votes in Oasmia Pharmaceutical AB (publ) amounts to 81 772 330 as of November 30, 2012. The increase in the number of shares is attributable to the new share issue with preferential rights for current shareholders carried out in October/November 2012, which comprised 24 531 699 shares.  The share issue was registered in its entirety with the Swedish Companies Registration Office on November 21, 2012.

A list of the company principal shareholders will be available at www.oasmia.com

This press release contains information which Oasmia is required to provide according to Financial Instruments Trading Act (1991:980) and/or the Securities Act (2007:528). The information was published on November 30, 2012 at 9.50.

About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatics which, in comparison with current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. The product development is based on in-house research within nanotechnology and company patents. The company was registered in 1999 and is located in Uppsala, Sweden.